Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2021-08-12 Annual Report
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서). It details specific corrections made to sections like 'Company Overview' and 'Dividend Information' in the original 2020 Annual Report. In the context of Korean regulatory filings (DART), a 'Business Report' (사업보고서) is the equivalent of an Annual Report (10-K). Since this document is a formal amendment/correction to that annual filing, it is classified as an Annual Report (10-K). FY 2020
2021-08-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is used to disclose changes in share ownership by major shareholders or insiders. In the provided taxonomy, this falls under 'Major Shareholding Notification' (MRQ) as it details the change in shareholding percentage and the nature of the transaction (a repurchase agreement).
2021-08-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required when an entity or individual crosses a significant ownership threshold (typically 5%) in a listed company. It details the reporting entity, special relations, number of shares held, and the purpose of the holding (often for management influence). This falls under the category of 'Major Shareholding Notification'.
2021-08-11 Korean
[기재정정]주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as the '5% Rule' report). It details the acquisition of convertible bonds and changes in shareholding status by the reporting entity (Kalia Investment Association) and its special related parties in the company 'Vivozon Healthcare'. This falls under the category of Major Shareholding Notification.
2021-08-04 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the shareholding status, changes in ownership, and conversion of convertible bonds (CB) by the reporting entity (Kallia Investment Association) and its special related parties in the issuer (Vivazon Healthcare). This fits the definition of a Major Shareholding Notification.
2021-08-04 Korean
[기재정정]전환청구권행사(제13회차, 제16회차)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (Vivozon Healthcare) regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This involves the issuance of new shares upon conversion, which directly impacts the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2021-07-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.